- ASSISTANT PROFESSOR Medicine, Nephrology
M.D., Harbin Medical University
Heilongjiang Health Institute
M.S., City University of New York
Albert Einstein College of Medicine
Dr. Song is a scientist in computational biology. He has double degrees: medicine and computer science, and was well trained on Molecular Biology, Genetics and Computer Science. He has extensive experience in experimental biology and database management. His current goal is to develop a robust information management system on clinical specimen repository for personalized medicine.
He serves as a Director of IT Core Lab in the institute, develops and manages the Laboratory Information Management System (LIMS), integrates biomedical instruments into LIMS and automates the sample extraction and tracking pipeline.
Dr. Song is a Co-Investigator of the NIDDK-funded U01 grant ‘New York CKD Biomarker Program’.
ResearchIntegration of the custom database with the GeneTraffic (Microarray) database
Digital data from biological instruments will be automated and transformed into a central database system using the BioExper system, and QTL MATCHMAKER database, a tool that enables high throughput mappings of genes and large scale comparative genomic analysis between Homo sapiens, Mus musculus, and Rattus norvegicus. Applications carried out to date include the development of Animal Inventory and Reagent Management modules.
Development of a Computer Managed Comprehensive Platform (BioExper)
Cutting-edge technology will be employed to develop a web-based platform, including JAVA programming language, XML, Oracle database etc. The system will store research data in a central database system, and captures experimental data at single experimental steps. The system will enable easier and more efficient communication of data between medical researchers and provide a data analysis tool.
- Sample tracking and specimen repository management
- Next-generation sequencing data analysis
- Biomedical instruments integration into LIMS
Song Q, Yang G, Goff SP, Prasad VR. Mutagenesis of the Glu 89 residue in human immunodeficiency virus type 1(HIV-1) and HIV-2 reverse transcriptases: Effects on nucleoside analog-resistance. J Virol 1992 Dec; 66(12): 7568-7571.
Kew Y, Song Q, Prasad VR. Subunit-selective mutagenesis of Glu89 residue in human immunodeficiency virus reverse transcriptase: contribution of P66 and P51 subunits to nucleoside analog sensitivity, divalent cation preference and steady state kinetic properties. J Biol Chem 1994 May 27; 269(21): 15331-15336.
Yang G, Song Q, Prasad VR. Use of chimeric human immunodeficiency virus type 1 and type 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 1996 Apr 1; 11(4): 326-333.
Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manna J, Islam S, Castriota G, Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996 Mar 1; 271(5253): 1282-1285.
Mabie P, Mehler MF, Marmur R, Papavasiliou A, Song Q, Kessler JA. Bone morphogenetic proteins induce astroglial differentiation of oligodendroglial progenitor cells. J Neurosci 1997 Jun 1; 17(11): 4112-4120.
Zhang D, Mehlar MF, Song Q, Kessler JA. Development of bone morphogenetic protein receptors in the nervous system and possible roles in regulating trkC expression. J.Neurosci 1998 May 1; 18(9): 3314-3326.
Song Q, Mehler MF, Kessler JA. Bone morphogenetic proteins induce apoptosis and growth factor dependence of cultured sympathoadrenal progenitor cells. Developmental Biology 1998 Apr 1; 196(1): 119-127.
Star KV, Song Q, Zhu A, Böttinger EP. QTL MatchMaker: a multi-species quantitative trait loci (QTL) database and query system for annotation of genes and QTL. Nucleic acids research 2006 Jan; 34(Database issue).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Song did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.